Given the favorable toxicity profile of Albu-LiTCo, we employed a HLE strategy to prolong its circulation time, thereby increasing the probability of reaching the tumor and loco-regional lymph nodes, to block the PD-1/PD-L1 axis and provide PD-L1-specific 4-1BB costimulation to induce the proliferation and survival of antigen primed tumor-reactive T cells. The gene discussed is TNFRSF9; the disease is neoplasm.